Brief: Aelis Farma Enrolls First Patient In Phase 2B Study Of AEF0117

Aelis Farma SA

01/06/2022 08:26

June 1 (Reuters) - Aelis Farma SA  AELIS.PA :
    * AELIS FARMA ANNOUNCES THE INCLUSION OF THE 1ST PATIENT IN
A
PHASE 2B STUDY OF AEF0117 FOR THE TREATMENT OF CANNABIS USE
DISORDER (CUD)
    * STUDY WILL BE COORDINATED BY COLUMBIA UNIVERSITY AND
CONDUCTED
AT 9 CLINICAL CENTERS IN UNITED STATES
    * IT IS EXPECTED TO INCLUDE APPROXIMATELY 330 PATIENTS AND
PROVIDE
RESULTS IN 2024
    * PHASE 2B CLINICAL TRIAL AIMS TO DEMONSTRATE EFFICACY OF
AEF0117
FOR TREATMENT OF CANNABIS USE DISORDER
    * PRIMARY OBJECTIVE OF STUDY IS TO DEMONSTRATE IF AEF0117
REDUCES
CANNABIS USE
    * PROPORTION OF PATIENTS REACHING OTHER LEVELS OF REDUCTION
OF USE
AND POTENTIAL IMPROVEMENT OF THEIR QUALITY OF LIFE WILL ALSO BE
INVESTIGATED

Source text for Eikon:  ID:nBw62NTpFa 
Further company coverage:  AELIS.PA 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))